Evidence map›Paper›PMID 24710571›Full record

ReviewArchives of toxicology2014

LC-MS-based metabolomics: an update.

Zhong-Ze Fang, Frank J Gonzalez

Open access · greenAbstract readReview
In one paragraph

Review in Archives of toxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 91 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Mechanism of the Effect of CompoundDrug design, development and therapy · 2023
    Article
  8. Article
  9. Article
  10. Review
  11. Tracer-Based Cancer Metabolomic Analysis.Advances in experimental medicine and biology · 2021
    Article
  12. Article
  13. Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2Drug metabolism and disposition: the biological fate of chemicals · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Blood type biochemistry and human disease.Wiley interdisciplinary reviews. Systems biology and medicine · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zhong-Ze FangLaboratory of Metabolism, Center for Cancer Research, National Institutes of Health, Bethesda, MD, 20892, USA.
Frank J Gonzalez
Center for Cancer Research · US

Funding

Xenobiotic receptorsZIABC005562 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONZALEZ, FRANK J · 2009 to 2025
$26.9M
Xenobiotic ReceptorsZIABC005708 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONZALEZ, FRANK J · 2009 to 2025
$16.4M
Optimized Metabolite Extraction, Separation, and Identification for MetabolomicsR01ES022186 · NIEHS · PENNSYLVANIA STATE UNIVERSITY, THE · PI PATTERSON, ANDREW · 2012 to 2016
$2.0M
Xenobiotic-Metabolizing EnzymesZ01BC005562 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONZALEZ, FRANK J · 1996 to 2008
$1.3M
Intramural NIH HHS Z01 BC005562NIEHS NIH HHS 1R01ES022186-01NIEHS NIH HHS R01 ES022186
6 · The paper itself

Abstract

Liquid chromatography-mass spectrometry (LC-MS)-based metabolomics can have a major impact in multiple research fields, especially when combined with other technologies, such as stable isotope tracers and genetically modified mice. This review highlights recent applications of metabolomic technology in the study of xenobiotic metabolism and toxicity, and the understanding of disease pathogenesis and therapeutics. Metabolomics has been employed to study metabolism of noscapine, an aryl hydrocarbon receptor antagonist, and to determine the mechanisms of liver toxicities of rifampicin and isoniazid, trichloroethylene, and gemfibrozil. Metabolomics-based insights into the pathogenesis of inflammatory bowel disease, alcohol-induced liver diseases, non-alcoholic steatohepatitis, and farnesoid X receptor signaling pathway-based therapeutic target discovery will also be discussed. Limitations in metabolomics technology such as sample preparation and lack of LC-MS databases and metabolite standards, need to be resolved in order to improve and broaden the application of metabolomic studies.

Indexed as

Chromatography, LiquidMass SpectrometryAnimalsBiotransformationDiseaseHumansMetabolomicsPharmaceutical PreparationsXenobioticsPharmaceutical PreparationsXenobiotics

Identifiers

PMID24710571
PMCPMC6310611
OpenAlexW2003991063

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.